High Throughput 96- & 384-Well DNA Purificati?on
MagSi-DNA cleanFIX from AMSBIO offers a cost effective solution for purifying DNA fragments, removing all unwanted side products and reagents, such as single nucleotides, terminator dyes, primers and primer dimers, enzymes, buffers and salts.
In many genomics applications, purification of DNA fragments is required to prevent downstream interference with analysis methods. Purification of PCR reactions often requires removal of dNTPs, primers, enzymes, salt by-products and various additives. Historically purification protocols have involved different sample types, different volumes and often multiple washing and centrifugation steps. Using such methods the errors incurred during sample preparation have resulted in lost time and significant costs due to re-work and lost reagents.
MagSi-DNA cleanFIX enables a combination of PCR clean-up and dye terminator removal from sequence reaction mixes with a single product. The kit uses magnetic silica bead technology, and is easily automated because no columns or centrifugation steps are involved. The kit uses a simple “Bind, Wash & Elute” procedure common to magnetic particle purification protocols.
Independent test results demonstrate how MagSi-DNA cleanFIX purification methods developed for a commercial liquid handling workstation provide an automated walk-away solution for PCR clean-up and dye terminator removal from sequence reactions. The precision and reproducibility of the workstation in combination with the customized magnets for MagSi-DNA cleanFIX are shown to allow fast magnetic separation and homogenization of the samples. Overall the PCR clean-up protocol using MagSi-DNA cleanFIX is shown to enable fast and efficient recovery of DNA fragments larger than 80 bp with >99% removal of primers and primer dimers. In addition the dye terminator removal method consistently delivered high quality sequence data with Phred >20 scores above 700.
For further information on MagSi-DNA cleanFIX and the fully range of magnetic beads available from AMSBIO please visit www.amsbio.com/DNA-sequencing-
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...